Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 162 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergens Clear all
Completed Not applicable Interventional Results available

Imaging Study of the Lungs During an Allergic Asthma Attack

NCT01547286
View directory record Official record
Conditions
Asthma, Atopy
Interventions
Standardized Cat Allergen Extract and Standardized Dust Mite Allergen, Computed Tomography imaging, functional Positron Emission Tomography imaging, Nebulized methacholine inhalation
Biological · Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 24, 2026, 10:22 PM EDT
Terminated No phase listed Observational

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

NCT02601690
View directory record Official record
Conditions
Allergy
Interventions
Blood Sampling
Other
Lead sponsor
Adiga Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Upland, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 24, 2026, 10:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Food Allergen Eliminations and Combined Protocols for Obesity Reduction: a Preliminary Comparison Study

NCT03821818
View directory record Official record
Conditions
Obesity
Interventions
Food Allergy Elimination + Willis Exercise
Behavioral
Lead sponsor
Galveston Clinical Research Foundation
Other
Eligibility
20 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

NCT00346398
View directory record Official record
Conditions
Asthma, Allergic Sensitization
Interventions
Oral mucosal immunoprophylaxis (OMIP), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 30 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

NCT00557284
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Montelukast, Placebo
Drug
Lead sponsor
1st Allergy & Clinical Research Center
Other
Eligibility
1 Year to 8 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Centennial, Colorado • Thornton, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

NCT03352726
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 IHRP
Drug
Lead sponsor
DBV Technologies
Industry
Eligibility
12 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

NCT00640250
View directory record Official record
Conditions
Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Factors Involved in Asthma and Airway Inflammation

NCT00001887
View directory record Official record
Conditions
Asthma, Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

NCT00769886
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational

The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

NCT01318954
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Allergen immunotherapy
Biological
Lead sponsor
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

A Study Of TL-925 For The Treatment of AC

NCT06293820
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Not applicable Interventional

The Allergen Reduction and Child Health Study (ARCHS)

NCT04331353
View directory record Official record
Conditions
Asthma in Children
Interventions
Comparator 1 (tailored approach), Comparator 2 (insecticidal bait)
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
5 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

NCT00836368
View directory record Official record
Conditions
Allergic, Asthmatic, Allergy, Asthma
Interventions
gamma-tocopherol
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101
View directory record Official record
Conditions
Nasal Allergy
Interventions
Nasal lavage, Nasal allergen challenge, Epicutaneous skin testing, Peripheral blood, Montelukast 10Mg Tablet, Placebo Oral Tablet
Procedure · Drug
Lead sponsor
Mitchell Grayson
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

NCT00241319
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lewiston, Maine • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 24, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

NCT00483041
View directory record Official record
Conditions
Asthma
Interventions
PLACEBO, MEDI528 9 mg/kg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational

Ragweed Observational Study

NCT01398137
View directory record Official record
Conditions
Ragweed Allergy
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

NCT03479307
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Early Allergen System Experience

NCT06262867
View directory record Official record
Conditions
Food Allergy in Infants
Interventions
Ready. Set. Food! Stage 1 Mix ins
Dietary Supplement
Lead sponsor
Prollergy dba Ready Set Food
Other
Eligibility
2 Months to 5 Months
Enrollment
1,110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 24, 2026, 10:22 PM EDT